VITA 34 AG Stock BOERSE MUENCHEN

Equities

V3V

DE000A0BL849

Healthcare Facilities & Services

Real-time BOERSE MUENCHEN 05:44:07 2024-07-04 EDT 5-day change 1st Jan Change
4.5 EUR +1.81% Intraday chart for VITA 34 AG -3.49% -15.97%

Financials

Sales 2024 * 81M 87.48M 119M Sales 2025 * 83.4M 90.07M 123M Capitalization 78.44M 84.71M 115M
Net income 2024 * -1M -1.08M -1.47M Net income 2025 * - 0 0 EV / Sales 2024 * 0.97 x
Net cash position 2024 * 200K 216K 294K Net cash position 2025 * 7.3M 7.88M 10.74M EV / Sales 2025 * 0.85 x
P/E ratio 2024 *
-56.3 x
P/E ratio 2025 *
-225 x
Employees -
Yield 2024 *
-
Yield 2025 *
-
Free-Float 30.42%
More Fundamentals * Assessed data
Dynamic Chart
1 week-3.49%
Current month-1.34%
1 month-7.53%
3 months-14.17%
6 months-15.97%
Current year-15.97%
More quotes
1 week
4.40
Extreme 4.4
4.58
1 month
4.40
Extreme 4.4
5.00
3 years
3.81
Extreme 3.81
17.15
More quotes
Managers TitleAgeSince
Chief Executive Officer 52 22-03-21
Director of Finance/CFO - 22-07-31
Investor Relations Contact - -
Members of the board TitleAgeSince
Director/Board Member 49 20-06-30
Chairman 59 21-12-14
Director/Board Member 52 -
More insiders
Date Price Change
24-07-04 4.5 +1.81%
24-07-03 4.42 -0.90%
24-07-02 4.46 0.00%
24-07-01 4.46 -0.45%
24-06-28 4.48 -0.88%

Real-time BOERSE MUENCHEN, July 04, 2024 at 05:44 am

More quotes
Vita 34 International AG is a Germany-based company engaged in the medical technology sector. The Company is involved in the long-term storage and processing of stem cells from human umbilical cord blood. The cells are collected at the child’s birth and can be used later in his or her life for the treatment of many diseases, such as anemia, diabetes, degenerative joint diseases, cancer, neurological deficits after brain injuries, cartilage damages and others. They also allow the growing of whole organs, such as the liver. On average, one out seven individuals, whose cells are stored, receives autologous stem cell transplant by the age of 70. The Company acts as a cord blood bank and is also engaged in research activities in the area of regenerative medicine, including curing the consequences of strokes and heart attacks. The Company operates in Germany, Spain and Denmark.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
4.5 EUR
Average target price
6 EUR
Spread / Average Target
+33.33%
Consensus

Annual profits - Rate of surprise